Very Low Carbohydrate Diets & Glucagon Response in T1DM

Status Recruiting

Clinical Trial Summary

Despite major technological advances, management of type one diabetes mellitus (T1D) remains suboptimal, putting millions of people at risk for immediate and long-term complications. After meals, a mismatch between carbohydrate absorption rate and insulin action typically leads to alternating periods of hyper- and hypoglycemia. A conceptually promising approach to control both problems is dietary carbohydrate restriction to reduce postprandial blood glucose changes and insulin needs. In a prior survey study, the investigators documented exceptional glycemic control (HbA1c 5.67%) and low acute complication rates among 316 children and adults with T1D consuming a very-low-carbohydrate (VLC) diet. Despite these promising preliminary results, the use of VLC diets for T1D remain controversial, because of their restrictive nature and theoretical concerns regarding growth, ketoacidosis and hypoglycemia risks and efficiency of glucagon treatment for hypoglycemia. Glucagon is used as a rescue medication during severe hypoglycemia and increases blood glucose levels by mobilizing liver glycogen stores. If these stores are depleted during carbohydrate restriction, glucagon response may be inadequate and put individuals at risk for refractory hypoglycemia. A physiologic study has shown a blunted but still adequate response to glucagon in n=10 participants after following a VLCD for 1 week. Longer-term studies have not been done. To test the hypotheses that glucagon response remains adequate while following a VLC diet in the longer term, the investigators will conduct a glucagon challenge in participants who are assigned to the VLC arm of a randomized-controlled feeding study in 32 young adults with T1D who will receive a VLC vs a standard diet for 12 weeks. After an overnight fast, twelve participants in the VLC arm will receive IV insulin to lower blood glucose levels to 60 mg/dL, followed by a glucagon injection and monitoring of blood glucose levels and other metabolic fuels.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04200391
Study type	Interventional
Source	Boston Children's Hospital
Contact	Belinda S Lennerz, MD, PhD
Phone	8572183896
Email	belinda.lennerz@childrens.harvard.edu
Status	Recruiting
Phase	N/A
Start date	January 3, 2020
Completion date	July 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03886974` - Transition to Adult Care in Type 1 Diabetes
Completed	`NCT05620251` - Response to BNT162b2 Vaccine in Adolescents With Type 1 Diabetes
Completed	`NCT03623113` - The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes	N/A
Active, not recruiting	`NCT05078658` - Low-carbohydrate Diet in Children With Type 1 Diabetes	N/A
Not yet recruiting	`NCT06018324` - CloudCare in the Treatment of Type 1 Diabetes in Pediatrics
Withdrawn	`NCT03736083` - Introducing CGM at Type 1 Diabetes Diagnosis	N/A
Completed	`NCT03177096` - Impact of the Continuous Measurement of Blood Glucose on Insulin Pump on Child Quality of Life With Type 1 Diabetes	N/A
Not yet recruiting	`NCT06418269` - The Effect of Therapeutic Play on Anxiety and Fear Levels in Children With Diabetes	N/A
Completed	`NCT04172077` - Self Efficacy Levels, Attachment Style and Resiliency of Youth With Type 1 Diabetes
Recruiting	`NCT04950634` - Sexual Dimorphism in Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes
Completed	`NCT04450745` - Physical Exercise in Normobaric Hypoxia and Normoxia in Type 1 Diabetic Patients	N/A
Completed	`NCT03165786` - A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes	N/A
Terminated	`NCT04028960` - IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase	Phase 2
Recruiting	`NCT05324488` - Diabetes Registry Graz for Biomarker Research
Completed	`NCT02984709` - Check It! 2.0: Positive Psychology Intervention for Adolescents With Type 1 Diabetes	N/A
Completed	`NCT02984514` - Brown Adipose Tissue in Type 1 Diabetes	N/A
Recruiting	`NCT06372392` - Universal Fixed Meal Boluses Usage in Patients With Medtronic Minimed 780G Pumps	N/A
Recruiting	`NCT05973799` - Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes	N/A
Recruiting	`NCT03311516` - New Insulin Therapy by Multiwave Bolus	N/A
Completed	`NCT03711656` - Prediction and Prevention of Nocturnal Hypoglycemia in Persons With Type 1 Diabetes Using Machine Learning Techniques	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Very Low Carbohydrate Diets and Glucagon Response in T1DM

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms